IQVIA's AI-Fueled Acceleration: A Rare Clean Quarter and a Raised Guide
The Clean Quarter
IQVIA delivered a quarter so unblemished that even CEO Ari Bousbib underscored its rarity:
The numbers back him up. Revenue rose 8.7% reported (8.5% constant currency), adjusted EBITDA grew 9.2%, and adjusted EPS jumped 12.1% to $3.15—all above the high end of guidance. The company raised its full-year outlook on all three metrics, with organic revenue growth guidance midpoint up 100 basis points to 6.5%.I have to tell you, in over 25 years of reporting earnings in these or other companies, I have never had as clean a quarter as this one. All around. I must tell you, there is absolutely nothing salient, unusual, abnormal, odd, untoward in our numbers. Anywhere.
The operational engine was win rate improvement, now showing in both segments. R&DS net new bookings hit $3.15B (book-to-bill 1.22), the highest since 2022, while Commercial Solutions organic growth accelerated to 5%—double the prior-year pace. As Bousbib put it: “There was strength literally across the board. Nothing unusual. Pass throughs were in the normal range. Cancellations were in the normal range. Good mix of large, mid, EBP.”
AI as the Differentiator
AI is no longer theoretical. use of AI is now baked into the sales pitch and the delivery model. Management cited 294 agents deployed across 90 use cases, with customers moving beyond pilots into production. One midsized pharma is expanding an IQVIA AI immunology franchise across 95 countries; a top-5 pharma is deploying an enterprise AI analytics solution. These wins are translating into “four of the top 10 pharma companies have already contracted with us to co-develop AI solutions, and 19 of the top 20 have deployed solutions in their workflow.” — Ari Bousbib, Chairman and Chief Executive Officer · 2026-07-28
The AI narrative directly connects to the bookings momentum. AI in discovery is driving more molecules into development, which increases demand for CRO services—not replaces them. As Bousbib noted, clients are asking IQVIA to “gear up capacity as additional molecules will enter development.” This is a structural tailwind, not a one-off.
EBP and the Redefined Market
IQVIA also redefined its customer segmentation, clarifying that EBP segment (emerging biopharma) now represents 35% of R&DS revenue—the largest among CRO peers. This is strategically important because EBP clinical trial starts have grown from 45% a decade ago to ~70% today, and EBP R&D spend is growing 2–3x faster than large pharma. The company's strong positioning here is a key reason for the above-market bookings growth.
This focus is a continuation of prior themes, but the clarity is new. In a prior call, Bousbib had emphasized the same point: “AI justification is a positive, has been a positive, will continue to be a positive for us.” — Ari Bousbib, Chairman and Chief Executive Officer · 2026-02-05 Now it's backed by hard numbers.
Margins and the Road Ahead
Adjusted EBITDA margin expanded 10 bps in the quarter, driven by operational productivity. CFO Mike Fedock explained: “operational productivity programs are going exceptionally well. And we said that AI is just another lever in that toolkit. So that drove about 90 basis points of operational margin expansion in the quarter.” — Michael J. Fedock, Executive Vice President and Chief Financial Officer · 2026-07-28 The margin is still flat year-over-year at ~23.2% for the full year, but the operational lever is clearly working.
The stock has reacted accordingly: Price-to-revenue at 1.7x remains well below the 2021 peak of 3.9x, suggesting room for further re-rating if the momentum holds.